【Everbright Securities: Progress Has Been Made In Various Drugs, And The Field Of Liver Fibrosis Treatment Is Developing Rapidly】According To The Everbright Securities Research Report, Liver Fibrosis Is Liver Damage Caused By Inflammation Or Metabolic Disorders. The Cause Can Be Induced By Various Factors Such As Alcohol, Viruses, And Fatty Liver Disease. Failure To Intervene In A Timely Manner May Lead To Cirrhosis Or Liver Cancer. However, There Is Currently A Lack Of Chemical Or Biological Drugs For The Treatment Of Liver Fibrosis. According To China'S “Guidelines For The Combined Diagnosis And Treatment Of Liver Fibrosis” (2019 Edition), Proprietary Chinese Medicines Are Used Clinically For Treatment, And Related Treatments Are Mainly Given To The Cause. In March 2024, Rezdiffra (Resmetirom), The First Innovative Drug To Treat Steatohepatitis (Mash) Associated With Metabolic Dysfunction, Was Officially Approved For Marketing By The FDA, Achieving A Breakthrough In The Treatment Of Liver Fibrosis. As Of November 2024, Several Drugs To Treat Liver Fibrosis Have Progressed Worldwide. From Biotech Companies Such As Golie Pharmaceuticals And Viking Therapeutics, To Major Pharmaceutical Companies Such As Bi And Novo Nordisk, All Published Positive Mash Treatment Data; In Addition, F351 (Oxynitone), A Treatment Drug For Hepatitis B Causing Fibrosis, Has Also Completed The Enrollment Of Patients In Phase 3 Clinical Trials, Making It The Fastest Progressing Product For Hepatitis B Fibrosis